September 14th 2023
Your daily dose of clinical news you may have missed.
September 6th 2023
New research shows that patients with heart failure who had more steps per day and increasing steps per day experienced better health status over 12 weeks.
September 1st 2023
August 29th 2023
The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.
August 28th 2023
ESC 2023: Early initiation of dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in patients hospitalized with ADHF.
Semaglutide 2.4 mg Significantly Reduces HF Symptom Burden, Body Weight in Adults with HFpEF and Obesity
ESC Congress 2023. The results of STEP-HFpEF could "change the nature of the conversation about the role of obesity in HFpEF," said PI Mikhail Kosiborod, MD.
Daily Dose: Effect of Sotagliflozin on Heart Failure-Related Events
A daily dose of clinical news on Patient Care you may have missed.
Sotagliflozin Cut Risk by >50% for HF Rehospitalization and CV Death when Started Before Discharge
A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.
7 New Approved Drugs for Primary Care: Q2 2023
The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?
Concentrated and Distributed Physical Activity Similarly Lower Risk for CV Events
Regardless of the pattern of physical activity, it may reduce risk across a spectrum of cardiovascular diseases, say study authors. So, just do it!
Daily Dose: Association of Population Wellbeing with Cardiovascular Outcomes
Higher Community Wellbeing Linked to Reduced CVD Mortality in Study of More than 3000 US Counties
Wellbeing is considered a measurable and modifiable community attribute that study authors show is correlated with CV outcomes.
Daily Dose: HF, CV Benefit of SGLT-2 Inhibition Consistent in T2D, CDK, HF
SGLT-2 Inhibitor HF, CV Benefit Found Consistent Across Populations with T2D, CKD, HF
SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.
Home Blood Pressure Monitoring among Older US Adults
Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.
Daily Dose: Adherence to GLP1RA, SGLT2i Therapies & Prescription Copayment Level
Lower Adherence with GLP1RA, SGLT2i Therapies Linked to Higher Prescription Copayments
In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.
FDA Approves SGLT-2/1 Inhibitor Sotagliflozin, Grants Broad Heart Failure Indication
The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.
COPD Increases Risk for Heart Failure in People who Experience AMI
“Patients with COPD who have AMI are less aggressively treated than those without COPD," leading to higher in-hospital mortality and long-term mortality,” wrote authors.
FDA Grants Dapagliflozin Label Expansion for Treatment of Full Spectrum of Heart Failure
The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with
HFmrEF or HFpEF.
AHA/ACC Release Scientific Statement on Benefits of Exercise Training in Persons with HFpEF
Studies on supervised exercise training in patients with chronic, stable HFpEF suggest substantial improvements in exercise capacity and QoL that may surpass those seen with medication.
Lifelong Bachelor Status Significant Predictor of Death in Men, Not Women, with Heart Failure
ACC 2023. In an analysis of patients with heart failure, never having been married was associated with worse survival compared with having been married.
Daily Dose: Comparison of Loop Diuretics Shows No Difference in Heart Failure Survival
Comparison of Loop Diuretics Shows No Difference in Heart Failure Survival
After hospital discharge for heart failure, adults treated with either furosemide or torsemide had similar mortality rates, according to results from the TRANSFORM-HF clinical trial.
2022 Clinical Guideline Toplines: Essential Summaries for Primary Care
Patient Care Guideline Toplines summarize newly revised and updated clinical recommendations from professional societies for convenient, at-a-glance review.
Bempedoic Acid Meets Primary Endpoint in Key Cardiovascular Outcomes Trial: CLEAR
Approved in 2020 as Nexletol, bempedoic acid as the first ATP citrate lyase inhibitor and oral non-statin therapy to meet the MACE-4 primary endpoint.
Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.
Cardiometabolic Disease Update: 12 Studies
Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.
SGLT2 Inhibitors May be "Optimal" Treatment for HFpEF, HFmrEF, a New Meta-analysis Suggests
SGLT-2 inhibitors and drugs to treat HFrEF were compared for efficacy in patients with HF with LVEF ≥40%.
Finerenone: FDA Expands Label to Include Cardiovascular Outcomes Trial Data
Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.
Early-onset Type 2 Diabetes Linked to Significantly Increased Risk for CVD in Later Life: Study
A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.
Decline in Physical Function Independently Associated with CVD Risk in Older Adults: ARIC Analysis
Physical performance scores used as a proxy for function in adults aged >65 years improved CVD risk prediction beyond traditional risk factors, study authors report.
NAFLD Raises Risk of Incident Heart Failure with Increased Risk as Disease Worsens
A diagnosis of NAFLD was associated with a 50% greater risk of new-onset heart failure in a meta-analysis comprised of more than 11 million individuals.
Strict Limits on Salt Intake May Increase Negative Outcomes in HFpEF
Patients with HFpEF who significantly restrict salt consumption have increased risk for cardiovascular and HF events and HF hospitalization, according to new research.
Chronic Kidney Disease Present in 1 in 10 Adults: Study of 2.4 Million People in 11 Countries
Chronic kidney disease is underdiagnosed and undertreated across major Western countries, according to findings of the new CaReMe CKD study.
2 Clarke Drive Cranbury, NJ 08512